Baird raised the firm’s price target on Editas Medicine (EDIT) to $6 from $4 and keeps an Outperform rating on the shares. The company’s Q2 results were inline with expectations as it continues to advance its in vivo editing programs, the analyst tells investors in a research note. The firm believes the announcement of a lead candidate in September could drive interest in the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT: